English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Saturday, August 24, 2024
日本厚生勞動省批准了莫德納公司針對SARS-COV-2 JN.1變異株的COVID-19 mRNA疫苗的部分變更申請
日本厚生劳动省批准了莫德纳公司针对SARS-COV-2 JN.1变异株的COVID-19 mRNA疫苗的部分变更申请
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
Tuesday, March 26, 2024
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Monday, December 11, 2023
Moderna公司回顧了在第二次環境、社會和治理(ESG)投資者活動中取得的進展和雄心
Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
Wednesday, July 5, 2023
Moderna Announces Global Regulatory Submissions for Its Respiratory Syncytial Virus (RSV) Vaccine, MRNA-1345
Wednesday, May 3, 2023
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
Moderna Announces Establishment of an Enterprise Solutions Hub and Commercial Operations in The Philippines
Tuesday, September 13, 2022
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575